to-BBB announces brain drug delivery pilot study with Janssen Pharmaceutica NV for CNS diseases
to-BBB is entering into a pilot study with Janssen Pharmaceutica NV (Janssen) to enhance delivery of drugs to the brain for central nervous system (CNS) diseases.
“We are very proud to join forces with Janssen” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Janssen’s rich history in neuroscience discovery and broad range of potential compounds for brain diseases, will hopefully lead to new therapeutic options for patients.”
Drug development for CNS disorders is hampered by the blood-brain barrier (BBB), which prevents the delivery of many drug candidates to their disease target in the brain. to-BBB's proprietary G-Technology® is a safe technology for drug delivery to the brain. It is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. Proof of concept with the G-Technology is demonstrated in several disease models, including pain, brain tumors and viral encephalitis. The pilot study with to-BBB will allow researchers of Janssen to investigate the capabilities of the G-Technology to enhance delivery of their investigational compounds to the brain.
Other news from the department business & finance
